Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Biol Blood Marrow Transplant ; 23(5): 820-829, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28192251

RESUMEN

Adult stem cell transplantation (SCT) patients with graft-versus-host-disease (GVHD) exhibit significant disruptions in gut microbial communities. These changes are associated with higher overall mortality and appear to be driven by specific antibiotic therapies. It is unclear whether pediatric SCT patients who develop GVHD exhibit similar antibiotic-induced gut microbiota community changes. Here, we show that pediatric SCT patients (from Children's Medical Center Dallas, n = 8, and Cincinnati Children's Hospital, n = 7) who developed GVHD showed a significant decline, up to 10-log fold, in gut anti-inflammatory Clostridia (AIC) compared with those without GVHD. In fact, the development of GVHD is significantly associated with this AIC decline and with cumulative antibiotic exposure, particularly antibiotics effective against anaerobic bacteria (P = .003, Firth logistic regression analysis). Using metagenomic shotgun sequencing analysis, we were able to identify specific commensal bacterial species, including AIC, that were significantly depleted in GVHD patients. We then used a preclinical GVHD model to verify our clinical observations. Clindamycin depleted AIC and exacerbated GVHD in mice, whereas oral AIC supplementation increased gut AIC levels and mitigated GVHD in mice. Together, these data suggest that an antibiotic-induced AIC depletion in the gut microbiota is associated with the development of GVHD in pediatric SCT patients.


Asunto(s)
Antibacterianos/efectos adversos , Enfermedad Injerto contra Huésped/inducido químicamente , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Adolescente , Animales , Antiinflamatorios/efectos adversos , Niño , Preescolar , Clindamicina/efectos adversos , Clindamicina/farmacología , Clostridium/patogenicidad , Microbioma Gastrointestinal/efectos de los fármacos , Enfermedad Injerto contra Huésped/etiología , Enfermedad Injerto contra Huésped/microbiología , Humanos , Lactante , Ratones , Proyectos Piloto
2.
Cell Host Microbe ; 23(4): 423-424, 2018 04 11.
Artículo en Inglés | MEDLINE | ID: mdl-29649435

RESUMEN

The host factors that modulate hematopoietic reconstitution after bone marrow transplantation are poorly understood. In this issue of Cell Host & Microbe, Staffas et al. (2018) demonstrate that gut microbiota play a critical role in immune reconstitution after bone marrow transplantation, partly through dietary energy harvest and uptake.


Asunto(s)
Trasplante de Médula Ósea , Reconstitución Inmune , Humanos , Microbiota
3.
Nat Med ; 21(7): 808-14, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26053625

RESUMEN

Candida albicans colonization is required for invasive disease. Unlike humans, adult mice with mature intact gut microbiota are resistant to C. albicans gastrointestinal (GI) colonization, but the factors that promote C. albicans colonization resistance are unknown. Here we demonstrate that commensal anaerobic bacteria-specifically clostridial Firmicutes (clusters IV and XIVa) and Bacteroidetes-are critical for maintaining C. albicans colonization resistance in mice. Using Bacteroides thetaiotamicron as a model organism, we find that hypoxia-inducible factor-1α (HIF-1α), a transcription factor important for activating innate immune effectors, and the antimicrobial peptide LL-37 (CRAMP in mice) are key determinants of C. albicans colonization resistance. Although antibiotic treatment enables C. albicans colonization, pharmacologic activation of colonic Hif1a induces CRAMP expression and results in a significant reduction of C. albicans GI colonization and a 50% decrease in mortality from invasive disease. In the setting of antibiotics, Hif1a and Camp (which encodes CRAMP) are required for B. thetaiotamicron-induced protection against C. albicans colonization of the gut. Thus, modulating C. albicans GI colonization by activation of gut mucosal immune effectors may represent a novel therapeutic approach for preventing invasive fungal disease in humans.


Asunto(s)
Bacteroides/fisiología , Candida albicans/crecimiento & desarrollo , Catelicidinas/metabolismo , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Péptidos Catiónicos Antimicrobianos , Bacteroides/efectos de los fármacos , Candida albicans/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Candidiasis/microbiología , Candidiasis/patología , Catelicidinas/genética , Recuento de Colonia Microbiana , Femenino , Tracto Gastrointestinal/efectos de los fármacos , Tracto Gastrointestinal/microbiología , Tracto Gastrointestinal/patología , Vida Libre de Gérmenes , Células HT29 , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Ratones Endogámicos C57BL , Mimosina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA